Two Falls, Nine Medications, and a Daughter in the Exam Room

Order by harm-to-benefit ratio and by whether the drug plausibly caused the presenting problem.

1. Zolpidem 10 mg nightly -- first. Z-drugs are flagged as potentially inappropriate in older adults: falls, hip fracture, delirium, next-morning impairment, and motor vehicle crashes. Ten milligrams is also above the recommended dose for women and older adults (5 mg). It is the drug most directly linked to a nighttime bathroom fall.
2. Oxybutynin -- second. Strongly anticholinergic, it contributes to falls, constipation, urinary retention, dry mouth, and cognitive impairment. It was added 6 months ago and her falls are recent -- a temporal clue worth acting on. Replace with behavioral urgency training first; if pharmacotherapy is still needed, a non-anticholinergic agent such as mirabegron is the alternative, weighed against its own BP effects.
3. Aspirin 81 mg -- third. She has no vascular disease; primary prevention with aspirin is not recommended for initiation at her age, and the bleeding risk (including intracranial hemorrhage in a faller) outweighs any plausible benefit. Stopping is clean, with no withdrawal syndrome.
4. Antihypertensives -- see the orthostasis discussion; sequencing matters here.
5. Omeprazole and atorvastatin -- lower priority. Review the PPI indication and consider deprescribing if there is no Barrett esophagus or ulcer history; continue the statin in a functionally independent 86-year-old with reasonable life expectancy.

One change at a time, with a defined reassessment interval, so that a new symptom can be attributed. Changing five drugs on one day produces an uninterpretable result.

This is orthostatic hypotension: a fall of at least 20 mmHg systolic or 10 mmHg diastolic within 3 minutes of standing -- here 32/16 mmHg. It is present whether or not she reports symptoms, and it is a modifiable fall risk.

The blunted heart rate response (70 to 78) is a clue, not a triviality. A normal compensatory response is a clear rise in heart rate; a rise of only 8 bpm suggests the beta-blocker is blocking the tachycardia that would otherwise defend her blood pressure. This reframes the problem: she is not simply over-treated while seated.

Therefore do not reflexively stop the lisinopril because her seated pressure is 148. That would trade one problem for another.

Plan:

• Reassess the metoprolol indication. If it is for hypertension only -- no prior MI, no heart failure, no atrial fibrillation requiring rate control -- it is the best candidate for a gradual taper, because removing it restores compensatory tachycardia. If there is a compelling cardiac indication, keep it and look elsewhere.
• If lisinopril is reduced instead, do so knowing her seated BP is not at goal, and plan to reassess standing BP rather than seated alone.
• Avoid adding a pressor agent (fludrocortisone, midadrine) before removing offending drugs and correcting volume status.
• Non-pharmacologic measures: rise in stages, adequate hydration, avoid large carbohydrate-heavy meals and hot showers, and consider compression stockings.
• Do not chase a seated systolic below 130 in a frail 86-year-old with orthostasis. A seated systolic in the 130-150 range with no standing drop is a better outcome than a perfect seated number and a fracture.
• Confirm measurement technique -- proper cuff size, 5 minutes seated, arm supported -- before acting on any of these numbers.

Beyond medications, a multifactorial fall assessment:

• Gait and balance: Timed Up and Go of 16 seconds exceeds the ~12-second threshold and indicates increased fall risk. Refer to physical therapy for balance and strength training -- this is the intervention with the best evidence.
• Vision (acuity, cataract, bifocals when walking outdoors), feet and footwear, and a home safety review -- night lighting, bathroom grab bars, a bedside commode to eliminate the nighttime trip that caused fall two.
• Vitamin D: 800 IU is reasonable; check a level if there is any question of deficiency.
• Bone health: a fall in an 86-year-old should prompt fracture-risk assessment (DEXA, FRAX) and treatment if indicated -- preventing the fall and preventing the fracture are separate tasks.
• Cognition and continence: both anticholinergic burden and the reason for the oxybutynin warrant a brief cognitive screen and a continence review.
• Cardiac: no syncope here, but if any future fall is unexplained, an ECG belongs in the workup.

Stopping zolpidem safely:

• Taper, do not stop abruptly. Reduce by roughly 25% every 2 weeks; abrupt discontinuation risks rebound insomnia that will be read as proof she needs it.
• Set expectations up front: sleep may be worse for 1-2 weeks before it improves, and her baseline sleep on the drug is likely already poor.
• Offer an evidence-based replacement: CBT-I is first-line for chronic insomnia and outperforms hypnotics at 6 months. Sleep hygiene alone is a weak substitute and should not be the entire offer.
• Name the risk in concrete terms: the fall and fracture risk, and that the drug's benefit for chronic insomnia is modest and diminishes with tolerance.
• Coordinate with one prescriber and tell the daughter the plan, so that a covering clinician or an after-hours visit does not restart it. Give her a written taper schedule -- verbal instructions are where deprescribing fails.